TAK-228 for Kidney Cancer

Recruiting in Palo Alto (17 mi)

+7 other locations

Overseen byBradley McGregor, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Bradley A. McGregor, MD

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This research study is investigating a drug as a possible treatment for metastatic renal cell carcinoma. The intervention involved in this study is TAK-228.

Research Team

Bradley McGregor, MD

Principal Investigator

Dana-Farber Cancer Institute

Eligibility Criteria

Adults with metastatic renal cell carcinoma (RCC) who have previously been treated. Clear cell RCC patients must have tried at least one anti-angiogenic and one PD-1 pathway blocker, unless not suitable. Non-clear cell RCC patients need to have had any cancer therapy before. Participants must be in good physical condition, able to understand the study, consent to it, and use contraception if sexually active.

Inclusion Criteria

My clear cell cancer has worsened after treatment with specific drugs, except if they were intolerable or harmful.

If my cancer initially responded to treatment but then got worse, I will need a new biopsy if it's safe.

I am 18 years old or older.

See 10 more

Exclusion Criteria

Treatment with any investigational products within 3 weeks before the first dose of study drug

My brain metastases have been treated and stable for over 4 weeks.

I haven't had a stroke or any artery procedures in the last 6 months.

See 11 more

Treatment Details

Interventions

TAK-228 (mTOR Inhibitor)

Trial OverviewThe trial is testing TAK-228 as a potential treatment for metastatic renal cell carcinoma. Patients will receive this drug to see how effective it is against their cancer after previous treatments.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: TAK-228Experimental Treatment1 Intervention

* TAK-228 will be taken orally on a weekly basis for 4 weeks per cycle * Dosage will be determined by the study team